Soy isoflavones sensitize cancer cells to radiotherapy

Free Radical Biology and Medicine

Volumn 51, Issue 2, 2011, Pages 289-298

  Hillman, Gilda G ^a,b   Singh Gupta, Vinita ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

DNA repair; Free radicals; Radiation; Soy isoflavones; Transcription factors

Indexed keywords

APE1 PROTEIN; DAIDZEIN; GENISTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOFLAVONE DERIVATIVE; NOVASOY; PLACEBO; REDOX EFFECTOR FACTOR 1; SOY ISOFLAVONE DERIVATIVE; STAT3 PROTEIN; SUNITINIB; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CANCER CELL; CANCER RADIOTHERAPY; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL INVASION; CELL KILLING; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DNA REPAIR; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; LUNG NON SMALL CELL CANCER; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIATION SAFETY; RADIOSENSITIVITY; RADIOSENSITIZATION; REVIEW; SIGNAL TRANSDUCTION; SOYBEAN; TRANSCRIPTION REGULATION; TUMOR CELL; TUMOR GROWTH;

ANIMALS; CELL LINE, TUMOR; HUMANS; ISOFLAVONES; NEOPLASMS; RADIATION TOLERANCE;

GLYCINE MAX;

EID: 79959334411     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2011.04.039     Document Type: Review

References (71)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics CA Cancer J. Clin. 60 2010 277 300
2. P. Greenwald Clinical trials in cancer prevention: current results and perspectives for the future J. Nutr. 134 2004 3507S 3512S (Pubitemid 39587597)
3. D.G. Bostwick, H.B. Burke, D. Djakiew, S. Euling, S.M. Ho, J. Landolph, H. Morrison, B. Sonawane, T. Shifflett, D.J. Waters, and B. Timms Human prostate cancer risk factors Cancer 101 2004 2371 2490 (Pubitemid 39505434)
4. N. Khan, F. Afaq, and H. Mukhtar Cancer chemoprevention through dietary antioxidants: progress and promise Antioxid. Redox Signal. 10 2008 475 510
5. F.H. Sarkar, and Y. Li Using chemopreventive agents to enhance the efficacy of cancer therapy Cancer Res. 66 2006 3347 3350
6. F.H. Sarkar, and Y. Li The role of isoflavones in cancer chemoprevention Front. Biosci. 9 2004 2714 2724
7. J.R. Hebert, T.G. Hurley, B.C. Olendzki, J. Teas, Y. Ma, and J.S. Hampl Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study J. Natl. Cancer Inst. 90 1998 1637 1647 (Pubitemid 28523438)
8. S. Banerjee, Y. Li, Z. Wang, and F.H. Sarkar Multi-targeted therapy of cancer by genistein Cancer Lett. 269 2008 226 242
9. G.G. Kuiper, J.G. Lemmen, B. Carlsson, J.C. Corton, S.H. Safe, P.T. van der Saag, B.B. van der, and J.A. Gustafsson Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta Endocrinology 139 1998 4252 4263 (Pubitemid 28513713)
10. N. Kurahashi, M. Iwasaki, S. Sasazuki, T. Otani, M. Inoue, and S. Tsugane Soy product and isoflavone consumption in relation to prostate cancer in Japanese men Cancer Epidemiol. Biomarkers Prev. 16 2007 538 545 (Pubitemid 46548658)
11. J.J. Raffoul, F.H. Sarkar, and G.G. Hillman Radiosensitization of prostate cancer by soy isoflavones Curr. Cancer Drug Targets 7 2007 759 765
12. G. Rimbach, C. Boesch-Saadatmandi, J. Frank, D. Fuchs, U. Wenzel, H. Daniel, W.L. Hall, and P.D. Weinberg Dietary isoflavones in the prevention of cardiovascular disease-a molecular perspective Food Chem. Toxicol. 46 2008 1308 1319 (Pubitemid 351258194)
13. D.C. Knight, and J.A. Eden A review of the clinical effects of phytoestrogens Obstet. Gynecol. 87 1996 897 904 (Pubitemid 26127148)
14. J.N. Davis, B. Singh, M. Bhuiyan, and F.H. Sarkar Genistein-induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells Nutr. Cancer 32 1998 123 131 (Pubitemid 29081398)
15. G.G. Hillman, J.D. Forman, O. Kucuk, M. Yudelev, R.L. Maughan, J. Rubio, A. Layer, S. Tekyi-Mensah, J. Abrams, and F.H. Sarkar Genistein potentiates the radiation effect on prostate carcinoma cells Clin. Cancer Res. 7 2001 382 390 (Pubitemid 32183043)
16. J.J. Raffoul, Y. Wang, O. Kucuk, J.D. Forman, F.H. Sarkar, and G.G. Hillman Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest BMC Cancer 6 2006 107
17. X. Xu, K.S. Harris, H.J. Wang, P.A. Murphy, and S. Hendrich Bioavailability of soybean isoflavones depends upon gut microflora in women J. Nutr. 125 1995 2307 2315
18. G.N. Thalmann, P.E. Anezinis, S.M. Chang, H.E. Zhau, E.E. Kim, V.L. Hopwood, S. Pathak, A.C. von Eschenbach, and L.W. Chung Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer Cancer Res. 54 1994 2577 2581 (Pubitemid 24173741)
19. V. Singh-Gupta, H. Zhang, C.K. Yunker, Z. Ahmad, D. Zwier, F.H. Sarkar, and G.G. Hillman Daidzein effect on hormone refractory prostate cancer in vitro and in vivo compared to genistein and soy extract: potentiation of radiotherapy Pharm. Res. 27 2010 1115 1127
20. J. van Rijn, and J. van den Berg Flavonoids as enhancers of X-ray-induced cell damage in hepatoma cells Clin. Cancer Res. 3 1997 1775 1779 (Pubitemid 27444717)
21. T. Akimoto, T. Nonaka, H. Ishikawa, H. Sakurai, J.I. Saitoh, T. Takahashi, and N. Mitsuhashi Genistein, a tyrosine kinase inhibitor, enhanced radiosensitivity in human esophageal cancer cell lines in vitro: possible involvement of inhibition of survival signal transduction pathways Int. J. Radiat. Oncol. Biol. Phys. 50 2001 195 201
22. S.X. Yan, Y. Ejima, R. Sasaki, S.S. Zheng, Y. Demizu, T. Soejima, and K. Sugimura Combination of genistein with ionizing radiation on androgen-independent prostate cancer cells Asian J. Androl. 6 2004 285 290 (Pubitemid 39654593)
23. C.M. Yashar, W.J. Spanos, D.D. Taylor, and C. Gercel-Taylor Potentiation of the radiation effect with genistein in cervical cancer cells Gynecol. Oncol. 99 2005 199 205 (Pubitemid 41354602)
24. B. Zhang, J.Y. Liu, J.S. Pan, S.P. Han, X.X. Yin, B. Wang, and G. Hu Combined treatment of ionizing radiation with genistein on cervical cancer HeLa cells J. Pharmacol. Sci. 102 2006 129 135 (Pubitemid 44440976)
25. M. Hussain, M. Banerjee, F.H. Sarkar, Z. Djuric, M.N. Pollak, D. Doerge, J. Fontana, S. Chinni, J. Davis, J. Forman, D.P. Wood, and O. Kucuk Soy isoflavones in the treatment of prostate cancer Nutr. Cancer 47 2003 111 117 (Pubitemid 38590881)
26. J.J. Raffoul, S. Banerjee, V. Singh-Gupta, Z.E. Knoll, A. Fite, H. Zhang, J. Abrams, F.H. Sarkar, and G.G. Hillman Down-regulation of apurinic/apyrimidinic endonuclease 1/redox factor-1 expression by soy isoflavones enhances prostate cancer radiotherapy in vitro and in vivo Cancer Res. 67 2007 2141 2149 (Pubitemid 46424233)
27. J.J. Raffoul, S. Banerjee, M. Che, Z.E. Knoll, D.R. Doerge, J. Abrams, O. Kucuk, F.H. Sarkar, and G.G. Hillman Soy isoflavones enhance radiotherapy in a metastatic prostate cancer model Int. J. Cancer 120 2007 2491 2498 (Pubitemid 46642139)
28. F.H. Lo, N.K. Mak, and K.N. Leung Studies on the anti-tumor activities of the soy isoflavone daidzein on murine neuroblastoma cells Biomed. Pharmacother. 61 2007 591 595 (Pubitemid 47562698)
29. E.J. Choi, and G.H. Kim Daidzein causes cell cycle arrest at the G1 and G2/M phases in human breast cancer MCF-7 and MDA-MB-453 cells Phytomedicine 15 2008 683 690
30. V. Singh-Gupta, M.C. Joiner, L. Runyan, C.K. Yunker, F.H. Sarkar, S. Miller, S. Gadgeel, A.A. Konski, and G.G. Hillman Soy isoflavones augment radiation effect by inhibiting APE1/Ref-1 DNA repair activity in non small cell lung cancer J. Thorac. Oncol. 6 2010 688 698
31. T.M. Pawlik, and K. Keyomarsi Role of cell cycle in mediating sensitivity to radiotherapy Int. J. Radiat. Oncol. Biol. Phys. 59 2004 928 942 (Pubitemid 38834285)
32. A.A. Geldof, M.A. Plaizier, I. Duivenvoorden, M. Ringelberg, R.T. Versteegh, D.W. Newling, and G.J. Teule Cell cycle perturbations and radiosensitization effects in a human prostate cancer cell line J. Cancer Res. Clin. Oncol. 129 2003 175 182 (Pubitemid 36583698)
33. S. Madhusudan, and I.D. Hickson DNA repair inhibition: a selective tumour targeting strategy Trends Mol. Med. 11 2005 503 511 (Pubitemid 41653291)
34. P. Subarsky, and R.P. Hill The hypoxic tumour microenvironment and metastatic progression Clin. Exp. Metastasis 20 2003 237 250 (Pubitemid 36513228)
35. M.L. Fishel, and M.R. Kelley The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target Mol. Aspects Med. 28 2007 375 395 (Pubitemid 47331610)
36. H. Harada, S. Kizaka-Kondoh, G. Li, S. Itasaka, K. Shibuya, M. Inoue, and M. Hiraoka Significance of HIF-1-active cells in angiogenesis and radioresistance Oncogene 26 2007 7508 7516 (Pubitemid 350207705)
37. A.R. Evans, M. Limp-Foster, and M.R. Kelley Going APE over ref-1 Mutat. Res. 461 2000 83 108
38. M.R. Kelley, L. Cheng, R. Foster, R. Tritt, J. Jiang, J. Broshears, and M. Koch Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer Clin. Cancer Res. 7 2001 824 830 (Pubitemid 32708717)
39. K.A. Robertson, H.A. Bullock, Y. Xu, R. Tritt, E. Zimmerman, T.M. Ulbright, R.S. Foster, L.H. Einhorn, and M.R. Kelley Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation Cancer Res. 61 2001 2220 2225 (Pubitemid 32692051)
40. D. Wang, M. Luo, and M.R. Kelley Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition Mol. Cancer Ther. 3 2004 679 686 (Pubitemid 39193748)
41. S.H. MacPhail, J.P. Banath, T.Y. Yu, E.H. Chu, H. Lambur, and P.L. Olive Expression of phosphorylated histone H2AX in cultured cell lines following exposure to X-rays Int. J. Radiat. Biol. 79 2003 351 358 (Pubitemid 36920536)
42. L. Geng, K.C. Cuneo, A. Fu, T. Tu, P.W. Atadja, and D.E. Hallahan Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer Cancer Res. 66 2006 11298 11304 (Pubitemid 46009960)
43. F.H. Sarkar, and Y. Li NF-kappaB: a potential target for cancer chemoprevention and therapy Front. Biosci. 13 2008 2950 2959 (Pubitemid 351589211)
44. Y. Li, and F.H. Sarkar Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway Clin. Cancer Res. 8 2002 2369 2377 (Pubitemid 34753612)
45. M. Karin Nuclear factor-kappaB in cancer development and progression Nature 441 2006 431 436 (Pubitemid 44050137)
46. S. Shukla, G.T. MacLennan, P. Fu, J. Patel, S.R. Marengo, M.I. Resnick, and S. Gupta Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression Neoplasia 6 2004 390 400 (Pubitemid 38924854)
47. K.M. Kim, Y. Zhang, B.Y. Kim, S.J. Jeong, S.A. Lee, G.D. Kim, A. Dritschilo, and M. Jung The p65 subunit of nuclear factor-kappaB is a molecular target for radiation sensitization of human squamous carcinoma cells Mol. Cancer Ther. 3 2004 693 698 (Pubitemid 39193750)
48. L.E. Huang, Z. Arany, D.M. Livingston, and H.F. Bunn Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit J. Biol. Chem. 271 1996 32253 32259 (Pubitemid 26422262)
49. V. Singh-Gupta, H. Zhang, S. Banerjee, D. Kong, J.J. Raffoul, F.H. Sarkar, and G.G. Hillman Radiation-induced HIF-1alpha cell survival pathway is inhibited by soy isoflavones in prostate cancer cells Int. J. Cancer 124 2009 1675 1684
50. X. Zhang, T. Kon, H. Wang, F. Li, Q. Huang, Z.N. Rabbani, J.P. Kirkpatrick, Z. Vujaskovic, M.W. Dewhirst, and C.Y. Li Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha Cancer Res. 64 2004 8139 8142 (Pubitemid 39491746)
51. B.J. Moeller, Y. Cao, C.Y. Li, and M.W. Dewhirst Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules Cancer Cell 5 2004 429 441 (Pubitemid 38610245)
52. Q. Xu, J. Briggs, S. Park, G. Niu, M. Kortylewski, S. Zhang, T. Gritsko, J. Turkson, H. Kay, G.L. Semenza, J.Q. Cheng, R. Jove, and H. Yu Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways Oncogene 24 2005 5552 5560 (Pubitemid 43119350)
53. M.J. Gray, J. Zhang, L.M. Ellis, G.L. Semenza, D.B. Evans, S.S. Watowich, and G.E. Gallick HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas Oncogene 24 2005 3110 3120 (Pubitemid 40695080)
54. J. Bektic, R. Guggenberger, I.E. Eder, A.E. Pelzer, A.P. Berger, G. Bartsch, and H. Klocker Molecular effects of the isoflavonoid genistein in prostate cancer Clin. Prostate Cancer 4 2005 124 129 (Pubitemid 41474608)
55. G.G. Hillman, Y. Wang, O. Kucuk, M. Che, D.R. Doerge, M. Yudelev, M.C. Joiner, B. Marples, J.D. Forman, and F.H. Sarkar Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model Mol. Cancer Ther. 3 2004 1271 1279 (Pubitemid 39440172)
56. Y. Wang, J.J. Raffoul, M. Che, D.R. Doerge, M.C. Joiner, O. Kucuk, F.H. Sarkar, and G.G. Hillman Prostate cancer treatment is enhanced by genistein in vitro and in vivo in a syngeneic orthotopic tumor model Radiat. Res. 166 2006 73 80 (Pubitemid 44051228)
57. G.G. Hillman, Y. Wang, M. Che, J.J. Raffoul, M. Yudelev, O. Kucuk, and F.H. Sarkar Progression of renal cell carcinoma is inhibited by genistein and radiation in an orthotopic model BMC Cancer 7 2007 4
58. C.A. Lamartiniere, M.S. Cotroneo, W.A. Fritz, J. Wang, R. Mentor-Marcel, and A. Elgavish Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate J. Nutr. 132 2002 552S 558S (Pubitemid 34208769)
59. L. Valentin-Blasini, B.C. Blount, S.P. Caudill, and L.L. Needham Urinary and serum concentrations of seven phytoestrogens in a human reference population subset J. Expo. Anal. Environ. Epidemiol. 13 2003 276 282 (Pubitemid 36999366)
60. M.M. Lee, S.L. Gomez, J.S. Chang, M. Wey, R.T. Wang, and A.W. Hsing Soy and isoflavone consumption in relation to prostate cancer risk in China Cancer Epidemiol. Biomarkers Prev. 12 2003 665 668 (Pubitemid 36899850)
61. G.A. Greendale, G. FitzGerald, M.H. Huang, B. Sternfeld, E. Gold, T. Seeman, S. Sherman, and M. Sowers Dietary soy isoflavones and bone mineral density: results from the study of women's health across the nation Am. J. Epidemiol. 155 2002 746 754 (Pubitemid 34297655)
62. G.G. Hillman, V. Singh-Gupta, H. Zhang, A.K. Al-Bashir, Y. Katkuri, M. Li, C.K. Yunker, A.D. Patel, J. Abrams, and E.M. Haacke Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors Neoplasia 11 2009 910 920
63. G.G. Hillman, V. Singh-Gupta, A.K. Al-Bashir, C.K. Yunker, M.C. Joiner, F.H. Sarkar, J. Abrams, and E.M. Haacke Monitoring sunitinib-induced vascular effects to optimize radiotherapy combined with soy isoflavones in murine xenograft tumor Transl. Oncol. 4 2011 110 121
64. W. Miltyk, C.N. Craciunescu, L. Fischer, R.A. Jeffcoat, M.A. Koch, W. Lopaczynski, C. Mahoney, R.A. Jeffcoat, J. Crowell, J. Paglieri, and S.H. Zeisel Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer Am. J. Clin. Nutr. 77 2003 875 882
65. L. Fischer, C. Mahoney, A.R. Jeffcoat, M.A. Koch, B.E. Thomas, J.L. Valentine, T. Stinchcombe, J. Boan, J.A. Crowell, and S.H. Zeisel Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasia Nutr. Cancer 48 2004 160 170 (Pubitemid 39045777)
66. N.B. Kumar, J.P. Krischer, K. Allen, D. Riccardi, K. Besterman-Dahan, R. Salup, L. Kang, P. Xu, and J. Pow-Sang A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer Nutr. Cancer 59 2007 163 168 (Pubitemid 350230733)
67. N.B. Kumar, J.P. Krischer, K. Allen, D. Riccardi, K. Besterman-Dahan, R. Salup, L. Kang, P. Xu, and J. Pow-Sang Safety of purified isoflavones in men with clinically localized prostate cancer Nutr. Cancer 59 2007 169 175 (Pubitemid 350230734)
68. M. Messina, O. Kucuk, and J.W. Lampe An overview of the health effects of isoflavones with an emphasis on prostate cancer risk and prostate-specific antigen levels J. AOAC Int. 89 2006 1121 1134 (Pubitemid 44972063)
69. U. Vaishampayan, M. Hussain, M. Banerjee, S. Seren, F.H. Sarkar, J. Fontana, J.D. Forman, M.L. Cher, I. Powell, J.E. Pontes, and O. Kucuk Lycopene and soy isoflavones in the treatment of prostate cancer Nutr. Cancer 59 2007 1 7 (Pubitemid 47549774)
70. B.F. El-Rayes, P.A. Philip, F.H. Sarkar, A.F. Shields, A.M. Ferris, K. Hess, A.O. Kaseb, M.M. Javle, G.R. Varadhachary, R.A. Wolff, and J.L. Abbruzzese A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer Invest. New Drugs 51 2011 694 699
71. I.U. Ahmad, J.D. Forman, F.H. Sarkar, G.G. Hillman, E. Heath, U. Vaishampayan, M.L. Cher, F. Andic, P.J. Rossi, and O. Kucuk Soy isoflavones in conjunction with radiation therapy in patients with prostate cancer Nutr. Cancer 62 2010 996 1000